N-oxygenation of clozapine by flavin-containing monooxygenase

Drug Metabolism and Disposition

Volumn 25, Issue 4, 1997, Pages 524-527

  Tugnait, Meera ^b   Hawes, Edward M ^a   McKay, Gordon ^b   Rettie, Allan E ^b   Haining, Robert L ^b   Midha, Kamal K ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLAVOPROTEIN; NEUROLEPTIC AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THIAMAZOLE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

CLOZAPINE; HUMANS; MICROSOMES, LIVER; OXYGEN; OXYGENASES;

EID: 0030989682     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. R. J. Baldessarini and F. R. Frankenburg: Clozapine: a novel antipsychotic agent. N. Engl. J. Med. 324, 746-754 (1991).
2. +-glucuronide in the urine of patients treated with clozapine using electrospray mass spectrometry. Biol. Mass Spectrom. 23, 147-148 (1994).
3. G.-Q. Zhang, G. McKay, J. W. Hubbard, and K. K. Midha: Application of electrospray mass spectrometry in the identification of intact glucuronide and sulphate conjugates of clozapine in rat. Xenobiotica 26, 541-550 (1996).
4. V. Fischer, B. Vogels, G. Maurer, and R. E. Tynes: The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J. Pharmacol. Exp. Ther. 260, 1355-1360 (1992).
5. M. PirMohamed, D. Williams, S. Madden, E. Templeton, and B. K. Park: Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther. 272, 984-990 (1995).
6. B. J. Ring, S. N. Binkley, M. Vandenbranden, and S. A. Wrighton: In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br. J. Clin. Pharmacol. 41, 181-186 (1996).
7. D. M. Ziegler and M. S. Gold: Oxidative metabolism of tertiary amines by human liver tissue. Xenobiotica 1, 325-326 (1971).
8. J. R. Cashman: Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem. Res. Toxicol. 8, 165-181 (1995).
9. M. P. Lawton, J. R. Cashman, T. Cresteil, C. T. Dolphin, A. A. Elfarra, R. N. Hines, E. Hodgson, T. Kimura, J. Ozols, I. R. Phillips, R. M. Philpot, L. L. Poulsen, A. E. Rettie, E. A. Shephard, D. E. Williams, and D. M. Ziegler: A nomenclature for the flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch. Biochem. Biophys. 308, 254-257 (1994).
10. C. T. Dolphin, T. E. Cullingford, E. A. Shephard, R. L. Smith, and I. R. Phillips: Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FMO4. Eur. J. Biochem. 235, 683-689 (1996).
11. B. J. Ring, S. N. Binkley, M. Vandenbranden, J. Catlow, T. J. Lindsay, T. Gillespie, L. K. Roskos, S. P. Swanson, and S. A. Wrighton: Interactions of olanzapine with human liver drug metabolizing enzymes in vitro. ISSX Proc. 8, 60 (1995).
12. S. S. Sofer and D. M. Ziegler: Microsomal mixed-function amine oxidase. Oxidation products of piperazine-substituted phenothiazine drugs. Drug Metab. Dispos. 6, 232-239 (1978).
13. G. Lin, G. McKay, and K. K. Midha: Characterization of metabolites of clozapine N-oxide in the rat by micro-column high performance liquid chromatography/mass spectrometry with electrospray interface. J. Pharm. Biomed. Anal. 14, 1561-1577 (1996).
14. A. J. M. Sadeque, A. C. Eddy, G. P. Meier, and A. E. Rettie: Stereoselective sulfoxidation by human flavin-containing monooxygenase. Evidence for catalytic diversity between hepatic, renal and fetal forms. Drug Metab. Dispos. 20, 832-839 (1992).
15. R. W. Estabrook, J. Peterson, J. Baron, and A. Hildebrandt: The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism. Methods Pharmacol. 1, 303-350 (1972).
16. A. E. Rettie, B. D. Bogucki, I. Lim, and G. P. Meier: Stereoselective sulfoxidation of a series of alkyl p-tolyl sulfides by microsomal and purified flavin-containing monooxygenase. Mol. Pharmacol. 37, 643-651 (1990).
17. E. J. Faeder and L. M. Siegel: A rapid method for the determination of FMN and FAD in mixtures. Anal. Biochem. 53, 332-336 (1973).
18. J. R. Cashman, J. Proudfoot, D. W. Pate, and T. Högberg: Stereoselective N-oxygenation of zimeldine and homozimeldine by the flavin-containing monooxygenase. Drug Metab. Dispos. 16, 616-622 (1988).
19. K. Itagaki, G. T. Carver, and R. M. Philpot: Expression and characterization of a modified flavin-containing monooxygenase 4 from humans. J. Biol. Chem. 271, 20102-20107 (1996).
20. G. L. Kedderis and D. E. Rickert: Loss of rat liver microsomal cytochrome P-450 during methimazole metabolism. Role of flavin-containing monooxygenase. Drug Metab. Dispos. 13, 58-61 (1985).
21. M. J. Byerly and C. L. DeVane: Pharmacokinetics of clozapine and risperidone: a review of recent literature. J. Clin. Psychopharmacol. 16, 177-187 (1996).
22. D. M. Ziegler: Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. Drug Metab. Rev. 19, 1-32 (1988).